Pacira Biosciences, Stock Probability Of Bankruptcy

PCRX Stock

USD 16.91 0.27 1.62%

Pacira BioSciences,'s odds of distress is under 30% at this time. It has slight probability of undergoing some form of financial crisis in the near future. Probability of bankruptcy shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Pacira balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Pacira BioSciences, Piotroski F Score and Pacira BioSciences, Altman Z Score analysis.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira BioSciences, guide.

Market Cap is likely to rise to about 1.7 B in 2024. Enterprise Value is likely to rise to about 1.8 B in 2024

Pacira BioSciences, Company probability of bankruptcy Analysis

Pacira BioSciences,'s Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Pacira BioSciences, Probability Of Bankruptcy

Less than 30%

Most of Pacira BioSciences,'s fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacira BioSciences, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Pacira BioSciences, probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Pacira BioSciences, odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Pacira BioSciences, financial health.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira BioSciences,. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira BioSciences, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.24)

Earnings Share

(1.98)

Revenue Per Share

15.006

Quarterly Revenue Growth

0.028

Return On Assets

0.0417

The market value of Pacira BioSciences, is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira BioSciences,'s value that differs from its market value or its book value, called intrinsic value, which is Pacira BioSciences,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira BioSciences,'s market value can be influenced by many factors that don't directly affect Pacira BioSciences,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pacira BioSciences,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira BioSciences, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira BioSciences,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Pacira Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Pacira BioSciences, is extremely important. It helps to project a fair market value of Pacira Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Pacira BioSciences,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pacira BioSciences,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pacira BioSciences,'s interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.96	0.46	0.95	0.32	0.58	0.97	0.96	0.36	0.92	0.86	0.44	0.94	0.63	0.95	-0.03	0.95	0.83	0.88	0.16	0.52	0.88	0.49	0.78
Total Stockholder Equity	0.96		0.5	0.91	0.38	0.6	0.93	0.98	0.39	0.79	0.76	0.26	0.9	0.64	0.97	0.05	0.98	0.81	0.88	0.11	0.33	0.91	0.61	0.88
Current Deferred Revenue	0.46	0.5		0.51	-0.1	0.51	0.47	0.43	0.69	0.36	0.51	-0.16	0.26	0.41	0.36	0.51	0.51	0.67	0.56	0.48	0.11	0.43	0.54	0.35
Net Debt	0.95	0.91	0.51		0.3	0.61	0.96	0.9	0.45	0.88	0.81	0.31	0.88	0.6	0.88	0.02	0.91	0.84	0.85	0.35	0.41	0.9	0.43	0.73
Retained Earnings	0.32	0.38	-0.1	0.3		0.04	0.29	0.37	-0.42	0.18	-0.07	-0.02	0.51	-0.31	0.4	-0.5	0.36	-0.09	0.02	-0.24	-0.12	0.55	0.3	0.6
Accounts Payable	0.58	0.6	0.51	0.61	0.04		0.67	0.6	0.5	0.54	0.6	-0.12	0.5	0.35	0.57	0.29	0.63	0.74	0.73	0.26	0.1	0.54	0.4	0.48
Long Term Debt	0.97	0.93	0.47	0.96	0.29	0.67		0.94	0.34	0.9	0.82	0.31	0.94	0.61	0.93	-0.08	0.93	0.85	0.86	0.17	0.43	0.86	0.45	0.74
Net Receivables	0.96	0.98	0.43	0.9	0.37	0.6	0.94		0.28	0.81	0.74	0.28	0.95	0.63	0.99	-0.09	0.99	0.79	0.86	0.0	0.35	0.89	0.53	0.87
Short Term Investments	0.36	0.39	0.69	0.45	-0.42	0.5	0.34	0.28		0.32	0.58	0.0	0.04	0.54	0.23	0.88	0.34	0.66	0.58	0.73	0.14	0.29	0.41	0.11
Total Liab	0.92	0.79	0.36	0.88	0.18	0.54	0.9	0.81	0.32		0.93	0.63	0.84	0.62	0.78	-0.07	0.77	0.79	0.85	0.27	0.7	0.77	0.28	0.58
Total Current Assets	0.86	0.76	0.51	0.81	-0.07	0.6	0.82	0.74	0.58	0.93		0.6	0.69	0.72	0.71	0.26	0.72	0.87	0.9	0.36	0.7	0.65	0.42	0.49
Short Term Debt	0.44	0.26	-0.16	0.31	-0.02	-0.12	0.31	0.28	0.0	0.63	0.6		0.37	0.28	0.28	-0.12	0.19	0.18	0.32	0.04	0.86	0.21	-0.06	0.06
Intangible Assets	0.94	0.9	0.26	0.88	0.51	0.5	0.94	0.95	0.04	0.84	0.69	0.37		0.48	0.95	-0.34	0.91	0.66	0.75	-0.09	0.39	0.87	0.42	0.82
Common Stock	0.63	0.64	0.41	0.6	-0.31	0.35	0.61	0.63	0.54	0.62	0.72	0.28	0.48		0.61	0.28	0.62	0.8	0.82	0.21	0.32	0.55	0.34	0.49
Property Plant Equipment	0.95	0.97	0.36	0.88	0.4	0.57	0.93	0.99	0.23	0.78	0.71	0.28	0.95	0.61		-0.12	0.98	0.75	0.83	-0.07	0.32	0.88	0.55	0.88
Net Tangible Assets	-0.03	0.05	0.51	0.02	-0.5	0.29	-0.08	-0.09	0.88	-0.07	0.26	-0.12	-0.34	0.28	-0.12		-0.03	0.3	0.25	0.58	-0.03	-0.05	0.34	-0.16
Good Will	0.95	0.98	0.51	0.91	0.36	0.63	0.93	0.99	0.34	0.77	0.72	0.19	0.91	0.62	0.98	-0.03		0.81	0.86	0.06	0.3	0.89	0.54	0.88
Long Term Debt Total	0.83	0.81	0.67	0.84	-0.09	0.74	0.85	0.79	0.66	0.79	0.87	0.18	0.66	0.8	0.75	0.3	0.81		0.94	0.4	0.36	0.71	0.5	0.62
Capital Surpluse	0.88	0.88	0.56	0.85	0.02	0.73	0.86	0.86	0.58	0.85	0.9	0.32	0.75	0.82	0.83	0.25	0.86	0.94		0.27	0.44	0.81	0.49	0.71
Long Term Investments	0.16	0.11	0.48	0.35	-0.24	0.26	0.17	0.0	0.73	0.27	0.36	0.04	-0.09	0.21	-0.07	0.58	0.06	0.4	0.27		0.17	0.19	-0.05	-0.13
Short Long Term Debt	0.52	0.33	0.11	0.41	-0.12	0.1	0.43	0.35	0.14	0.7	0.7	0.86	0.39	0.32	0.32	-0.03	0.3	0.36	0.44	0.17		0.22	-0.15	0.08
Net Invested Capital	0.88	0.91	0.43	0.9	0.55	0.54	0.86	0.89	0.29	0.77	0.65	0.21	0.87	0.55	0.88	-0.05	0.89	0.71	0.81	0.19	0.22		0.54	0.88
Net Working Capital	0.49	0.61	0.54	0.43	0.3	0.4	0.45	0.53	0.41	0.28	0.42	-0.06	0.42	0.34	0.55	0.34	0.54	0.5	0.49	-0.05	-0.15	0.54		0.62
Capital Stock	0.78	0.88	0.35	0.73	0.6	0.48	0.74	0.87	0.11	0.58	0.49	0.06	0.82	0.49	0.88	-0.16	0.88	0.62	0.71	-0.13	0.08	0.88	0.62

Click cells to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Competition

Predict Pacira BioSciences,

Based on the latest financial disclosure, Pacira BioSciences, has a Probability Of Bankruptcy of 30.0%. This is 30.7% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 24.68% higher than that of the company.

Pacira Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacira BioSciences,'s direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacira BioSciences, could also be used in its relative valuation, which is a method of valuing Pacira BioSciences, by comparing valuation metrics of similar companies.

Pacira BioSciences, is currently under evaluation in probability of bankruptcy category among its peers.

Pacira BioSciences, Main Bankruptcy Drivers

	2019	2020	2021	2022	2023	2024 (projected)
Return On Assets	(0.0133)	0.11	0.0202	0.009463	0.0266	0.028
Asset Turnover	0.51	0.33	0.26	0.4	0.43	0.34
Gross Profit Margin	0.74	0.75	0.72	0.7	0.73	0.38
Net Debt	273.7M	441.2M	543.3M	659.3M	432.7M	454.4M
Total Current Liabilities	107.7M	253.3M	521.1M	147.8M	97.4M	123.5M
Non Current Liabilities Total	368.4M	401.5M	823.8M	758.4M	606.9M	637.2M
Total Assets	831.1M	1.3B	2.1B	1.7B	1.6B	1.7B
Total Current Assets	408.6M	651.6M	866.0M	498.3M	510.0M	331.8M
Total Cash From Operating Activities	70.5M	77.0M	125.7M	145.3M	154.6M	162.4M

Pacira BioSciences, ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pacira BioSciences,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pacira BioSciences,'s managers, analysts, and investors.

Environmental

Governance

Social

Pacira Fundamentals

	Return On Equity	-0.11
	Return On Asset	0.0417
	Profit Margin	(0.13) %
	Operating Margin	0.13 %
	Current Valuation	971.4 M
	Shares Outstanding	46.17 M
	Shares Owned By Insiders	2.10 %
	Shares Owned By Institutions	97.90 %
	Number Of Shares Shorted	4.82 M
	Price To Earning	14.34 X
	Price To Book	1.04 X
	Price To Sales	1.12 X
	Revenue	674.98 M
	Gross Profit	393.23 M
	EBITDA	157.58 M
	Net Income	41.95 M
	Cash And Equivalents	316.39 M
	Cash Per Share	6.90 X
	Total Debt	586.04 M
	Debt To Equity	1.10 %
	Current Ratio	3.95 X
	Book Value Per Share	16.24 X
	Cash Flow From Operations	154.65 M
	Short Ratio	8.80 X
	Earnings Per Share	(1.98) X
	Price To Earnings To Growth	(3.83) X
	Target Price	18.0
	Number Of Employees	711
	Beta	0.82
	Market Capitalization	780.79 M
	Total Asset	1.57 B
	Retained Earnings	(106.8 M)
	Working Capital	412.61 M
	Current Asset	252.58 M
	Current Liabilities	149.79 M
	Net Asset	1.57 B

About Pacira BioSciences, Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pacira BioSciences,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira BioSciences, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira BioSciences, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pacira Biosciences, Stock Probability Of Bankruptcy

Pacira BioSciences, Company probability of bankruptcy Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current Pacira BioSciences, Probability Of Bankruptcy

Pacira Probability Of Bankruptcy Driver Correlations

Pacira Probability Of Bankruptcy Peer Comparison

Pacira BioSciences, Main Bankruptcy Drivers

Pacira BioSciences, ESG Sustainability

Pacira Fundamentals

About Pacira BioSciences, Fundamental Analysis

Also Currently Popular

Additional Tools for Pacira Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY